NVO Crashes 36% in 3 Months: Is This an Indication to Sell the Stock?

Novo Nordisk has fallen 36% over the past three months as a weak 2026 outlook, intensifying competition, and pricing pressure cloud the near-term growth story. The article notes that long-term pipeline promise remains, but the immediate setup is negative for fundamentals and investor sentiment.

Analysis

Novo Nordisk has fallen 36% over the past three months as a weak 2026 outlook, intensifying competition, and pricing pressure cloud the near-term growth story. The article notes that long-term pipeline promise remains, but the immediate setup is negative for fundamentals and investor sentiment.